Literature DB >> 33540932

The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model.

Yimei Jia1, Bassel Akache1, Gerard Agbayani1, Vandana Chandan1, Renu Dudani1, Blair A Harrison1, Lise Deschatelets1, Usha D Hemraz2, Edmond Lam2, Sophie Régnier2, Felicity C Stark1, Lakshmi Krishnan1, Michael J McCluskie1.   

Abstract

Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. SLA archaeosomes are a promising adjuvant candidate due to their ability to strongly stimulate both humoral and cytotoxic immune responses when simply admixed with an antigen. In the present study, we evaluated whether the adjuvant effects of SLA archaeosomes could be further enhanced when combined with other adjuvants. SLA archaeosomes were co-administered with five different Toll-like Receptor (TLR) agonists or the saponin QS-21 using ovalbumin as a model antigen in mice. Both humoral and cellular immune responses were greatly enhanced compared to either adjuvant alone when SLA archaeosomes were combined with either the TLR3 agonist poly(I:C) or the TLR9 agonist CpG. These results were also confirmed in a separate study using Hepatitis B surface antigen (HBsAg) and support the further evaluation of these adjuvant combinations.

Entities:  

Keywords:  archaeosome; glycolipid; sulfated lactosyl archaeol; vaccine adjuvant

Year:  2021        PMID： 33540932      PMCID： PMC7913188          DOI： 10.3390/pharmaceutics13020205

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN： 1999-4923            Impact factor:   6.321


  30 in total

Review 1.  Archaeal lipid vaccine adjuvants for induction of cell-mediated immunity.

Authors:  K Haq; Y Jia; L Krishnan
Journal:  Expert Rev Vaccines       Date:  2016-06-08       Impact factor: 5.217

2.  CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).

Authors:  Shawn R Makinen; Qin Zhu; Heather L Davis; Risini D Weeratna
Journal:  Int Immunol       Date:  2016-04-07       Impact factor: 4.823

Review 3.  Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.

Authors:  Giuseppe Del Giudice; Rino Rappuoli; Arnaud M Didierlaurent
Journal:  Semin Immunol       Date:  2018-05-23       Impact factor: 11.130

4.  A comparison of the immune responses induced by antigens in three different archaeosome-based vaccine formulations.

Authors:  Yimei Jia; Bassel Akache; Lise Deschatelets; Hui Qian; Renu Dudani; Blair A Harrison; Felicity C Stark; Vandana Chandan; Mohammad P Jamshidi; Lakshmi Krishnan; Michael J McCluskie
Journal:  Int J Pharm       Date:  2019-03-02       Impact factor: 5.875

5.  Archaeal glycolipid adjuvanted vaccines induce strong influenza-specific immune responses through direct immunization in young and aged mice or through passive maternal immunization.

Authors:  Felicity C Stark; Bassel Akache; Amalia Ponce; Renu Dudani; Lise Deschatelets; Yimei Jia; Janelle Sauvageau; Dean Williams; Mohammad P Jamshidi; Gerard Agbayani; Kristina Wachholz; Blair A Harrison; Xuguang Li; Lakshmi Krishnan; Wangxue Chen; Michael J McCluskie
Journal:  Vaccine       Date:  2019-08-02       Impact factor: 3.641

Review 6.  From discovery to licensure, the Adjuvant System story.

Authors:  Nathalie Garçon; Alberta Di Pasquale
Journal:  Hum Vaccin Immunother       Date:  2016-09-16       Impact factor: 3.452

7.  Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice.

Authors:  Bassel Akache; Felicity C Stark; Yimei Jia; Lise Deschatelets; Renu Dudani; Blair A Harrison; Gerard Agbayani; Dean Williams; Mohammad P Jamshidi; Lakshmi Krishnan; Michael J McCluskie
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

8.  Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins.

Authors:  Bassel Akache; Lise Deschatelets; Blair A Harrison; Renu Dudani; Felicity C Stark; Yimei Jia; Amir Landi; John L M Law; Michael Logan; Darren Hockman; Juthika Kundu; D Lorne Tyrrell; Lakshmi Krishnan; Michael Houghton; Michael J McCluskie
Journal:  Vaccines (Basel)       Date:  2019-12-03

9.  Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma.

Authors:  Felicity C Stark; Gerard Agbayani; Jagdeep K Sandhu; Bassel Akache; Charis McPherson; Lise Deschatelets; Renu Dudani; Melissa Hewitt; Yimei Jia; Lakshmi Krishnan; Michael J McCluskie
Journal:  Biomedicines       Date:  2019-11-23

10.  Mechanistic insight into the induction of cellular immune responses by encapsulated and admixed archaeosome-based vaccine formulations.

Authors:  Gerard Agbayani; Yimei Jia; Bassel Akache; Vandana Chandan; Umar Iqbal; Felicity C Stark; Lise Deschatelets; Edmond Lam; Usha D Hemraz; Sophie Régnier; Lakshmi Krishnan; Michael J McCluskie
Journal:  Hum Vaccin Immunother       Date:  2020-08-05       Impact factor: 3.452
View more
  3 in total

Review 1.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

2.  Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant.

Authors:  Bassel Akache; Tyler M Renner; Anh Tran; Lise Deschatelets; Renu Dudani; Blair A Harrison; Diana Duque; Julie Haukenfrers; Martin A Rossotti; Francis Gaudreault; Usha D Hemraz; Edmond Lam; Sophie Régnier; Wangxue Chen; Christian Gervais; Matthew Stuible; Lakshmi Krishnan; Yves Durocher; Michael J McCluskie
Journal:  Sci Rep       Date:  2021-11-08       Impact factor: 4.996

Review 3.  Archaeosomes and Gas Vesicles as Tools for Vaccine Development.

Authors:  Natalia Adamiak; Krzysztof T Krawczyk; Camille Locht; Magdalena Kowalewicz-Kulbat
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.